SLC12A7 encodes a solute carrier family 12 member that mediates electroneutral potassium-chloride cotransport when activated by cell swelling 1. In normal physiology, SLC12A7 is important for potassium recycling in the inner ear and cochlear hair cell survival 1, and may contribute to renal acid-base balance through basolateral chloride extrusion 1. In cancer biology, SLC12A7 has emerged as a significant oncogenic factor. The gene is frequently amplified and overexpressed across multiple cancer types, with copy number amplifications observed in 65-68% of adrenocortical carcinomas 2. SLC12A7 overexpression promotes malignant phenotypes including enhanced proliferation, migration, and invasion capacity 34. In hepatocellular carcinoma, SLC12A7 enhancement of these aggressive behaviors correlates with immune cell infiltration and checkpoint gene expression 3. At the mechanistic level, SLC12A7 amplification alters cell adhesion dynamics and promotes invasiveness through osmotic stress, bone morphogenetic protein, and Hippo signaling pathway alterations 4. In adrenocortical carcinoma, SLC12A7 overexpression correlates with IGF1 dysregulation, linking ion transport to growth factor signaling 5. Importantly, SLC12A7 has been identified as a potential transporter mediating drug resistance to erlotinib 6. These findings establish SLC12A7 as a prognostic biomarker and immunotherapeutic target across cancers.